Avient (AVNT) Q4 2007 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2007 earnings summary
10 Nov, 2026Executive summary
2007 sales were nearly flat as growth in Asia and specialty businesses offset a sharp Vinyl Business decline from weak residential construction; operating income and net income fell substantially.
The OxyVinyls divestiture reduced cyclical exposure and funded high-cost debt repayment, strengthening the balance sheet and enabling strategic investment.
Strategic priorities centered on specialization, globalization, commercial excellence and operational improvement, with specialty businesses contributing ~20% of total earnings.
Financial highlights
Sales were $2,642.7 million in 2007, up 1% YoY; operating income was $33.9 million vs. $190.6 million, and net income was $11.4 million vs. $122.9 million.
Basic and diluted EPS was $0.12 in 2007 vs. $1.33 in 2006; income before discontinued operations was $11.4 million vs. $125.6 million.
2007 income included a $31.5 million deferred tax benefit from the OxyVinyls sale, alongside $48.8 million in environmental expense and $12.8 million in debt redemption premiums.
Operating cash flow was $67.2 million vs. $111.7 million; investing activities provided $215.3 million, primarily from the OxyVinyls sale, while financing used $275.9 million, mainly for debt repayment.
Outlook and guidance
2008 sales growth was projected at 10%–12%, including GLS and NHPC; full-year earnings growth was expected from non-vinyl growth, operational improvements and lower interest expense.
Capital expenditures were estimated at $50–$60 million for 2008, primarily supporting strategic growth and manufacturing operations; profitable operations were expected to sustain available capital resources.
The 2011 objectives include specialty business gross margin of 25%–35%, 40% of revenue outside the U.S., a 25% vitality index, double-digit compound annual operating income growth and pretax ROIC above 15%.
Latest events from Avient
- FY06 earnings rebounded, but 2007 margin gains faced soft demand and chlorovinyl headwinds.AVNT
Q4 2006 - Late-year demand collapse and large one-time charges turned modest sales growth into a $272.9M loss.AVNT
Q4 2008 - Operating income recovered to $98.4M as cash strengthened despite a 24.8% sales decline.AVNT
Q4 2009 - Volume recovery and efficiency lifted FY2010 results, while tax and one-time gains boosted net income.AVNT
Q4 2010 - FY11 growth met a pension-driven Q4 operating loss and major portfolio changes.AVNT
Q4 2011 - Record adjusted EPS and a specialty-led mix shift offset soft markets and lower reported earnings.AVNT
Q4 2012 - Acquisitions drove FY13 growth, alongside a major divestiture gain and integration costs.AVNT
Q4 2013 - Record adjusted EPS and stronger specialty mix offset restructuring and pension charges.AVNT
Q4 2014 - Adjusted EPS rose 9%, as specialty growth offset revenue and DSS headwinds.AVNT
Q4 2015